eRAPID feasibility pilot study in pelvic radiotherapy
Research type
Research Study
Full title
eRAPID Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: Feasibility pilot study in radiotherapy.
IRAS ID
204978
Contact name
Galina Velikova
Contact email
Sponsor organisation
University of Leeds
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is an online system for patients to self-report symptoms and side effects (known as adverse events or AE) during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing Electronic Patient Records (EPR) to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
We have developed the eRAPID system as a complex intervention for use in patients undergoing pelvic radiotherapy specifically for prostate, cervical, vulval, anal, endometrial and rectal cancers. We have done this by:
1) Integrating QTool questionnaire data with the Christie Manchester electronic patient records system; clinical web portal (CWP) and in MOSAIQ (radiotherapy delivery system) in Leeds;
2) Developing tumour specific AE questionnaires and treatment algorithms for online reporting from home;
3) Mapping the current RT treatment pathways for these tumour groups via semi-structured interviews with staff and patients.The overall aims of the eRAPID system are to improve the safe delivery of cancer treatments, enhance patient care and standardise documentation of AE within the clinical datasets.
REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
16/YH/0371
Date of REC Opinion
13 Sep 2016
REC opinion
Favourable Opinion